Ergomed plc Earn-Out Shares and PDMR Dealing (9782V)
12 April 2019 - 4:00PM
UK Regulatory
TIDMERGO
RNS Number : 9782V
Ergomed plc
12 April 2019
Ergomed Issues Earn-Out Shares to Former Shareholders of
PharmInvent and PDMR Dealing
Guildford, UK - 12 April 2019: Ergomed plc (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry, today
announces the issue of 158,810 new ordinary shares of 1p each in
the Company ("Earn-Out Shares") to former shareholders of European
PharmInvent Services s.r.o. ("PharmInvent") (now named
PrimeVigilance s.r.o.).
The Board of Ergomed has approved the allotment and issue of the
Earn-Out Shares as part of the final payment of contingent
consideration for the acquisition of PharmInvent, announced on 29
November 2016. Under the terms of this deal, Ergomed acquired 100
per cent of the issued share capital of PharmInvent for an initial
consideration of EUR4.8 million (GBP4.1 million), with contingent
consideration based on the achievement of EBITDA targets for 2016,
2017 and 2018 of up to an aggregate further EUR3.2 million (GBP2.7
million). The initial and contingent consideration (earn-out) are
both satisfied 80% in cash and 20% in new Ergomed ordinary shares.
The Earn-Out Shares will be issued at a price of 152.975 pence per
share.
Dr Jan Petracek, Chief Operating Officer of the Company, will
receive 79,405 new ordinary shares at a price of 152.975 pence per
share as part of the issue of the Earn-Out Shares. Following the
issue of the Earn-Out Shares, Dr Petracek will hold 497,411
ordinary shares in the capital of the Company (representing 1.07
per cent. of the Company's issued share capital).
An application has been made for the admission to trading on AIM
of the Earn-Out Shares ("Admission"). Admission is expected to take
place on 16 April 2019. The Earn-Out Shares will rank pari passu in
all respects with Ergomed's existing shares in issue. Following
Admission, the Company's enlarged issue share capital will comprise
46,320,248 Ordinary Shares with one voting right per share. No
shares are held in Treasury. The total number of voting rights in
the Company is therefore 46,320,248. The figure of 46,320,248
ordinary shares may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Dr Jan Petracek
--------------------------------------- -------------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------------------------
a) Position/status Chief Operating Officer
--------------------------------------- -------------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------------
a) Name Ergomed plc
--------------------------------------- -------------------------------------------------------
b) Legal Entity 213800BVS8I9VMC1AP84
Identifier
--------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------------------
a) Description Ordinary shares of 1 pence each
of the financial
instrument,
type of instrument GB00BN7ZCY67
Identification
code
--------------------------------------- -------------------------------------------------------
b) Nature of the Acquisition of shares in relation to earn-out
transaction payment for the acquisition of European PharmInvent
Services s.r.o.
--------------------------------------- -------------------------------------------------------
c) Currency GBP
--------------------------------------- -------------------------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------------------------- -------------------------- ---------------------------
152.975p 79,405
-------------------------------------------- -------------------------- ---------------------------
e) Aggregated information Volume: 79,405
- Aggregated Price: 152.975p
volume Aggregated volume: GBP121,469.80
- Price
- Aggregated
total
--------------------------------------- -------------------------------------------------------
f) Date of the Admission of the shares expected on 16 April
transaction 2019
--------------------------------------- -------------------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------------------------- -------------------------------------------------------
Ends
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSFLESFFUSELL
(END) Dow Jones Newswires
April 12, 2019 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024